Search Results 11-20 of 21264 for anti-TNF drugs

  1. Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease - Mayo Clinic

    However, many CD and UC patients still ultimately require surgery despite the use of these medications. Side effects of the anti-TNF agents include increased ...

  2. Crohn's disease - Diagnosis and treatment - Mayo Clinic

    Infliximab (Remicade), adalimumab (Humira) and certolizumab pegol (Cimzia). Also known as TNF inhibitors, these drugs work by neutralizing an immune system ...

  3. Treatment response and management of biologics in patients with ECD - Mayo Clinic

    These include tumor necrosis factor-alpha (TNFα) inhibitors (certolizumab, infliximab, adalimumab), anti-integrin agents (vedolizumab, natalizumab), and ...

  4. Etanercept-Szzs (Subcutaneous Route) Description and Brand Names - Mayo Clinic

    Etanercept-szzs injection is used alone or with other medicines (eg, methotrexate) to reduce signs and symptoms of rheumatoid arthritis or psoriatic arthritis, ...

  5. Ulcerative Colitis Clinical Trials - Mayo Clinic Research

    ... medications such as the anti-Tumor Necrosis Factor (anti-TNF) agents infliximab, adalimumab, and certolizumab. However, many CD and UC patients still ...

  6. Ulcerative colitis - Diagnosis and treatment - Mayo Clinic

    Biologics · Infliximab (Remicade), adalimumab (Humira) and golimumab (Simponi). These medications, called tumor necrosis factor (TNF) inhibitors, work by ...

  7. Ankylosing spondylitis - Diagnosis & treatment - Mayo Clinic

    If nonsteroidal anti-inflammatory drugs (NSAIDs) aren't helpful, your doctor might suggest starting a tumor necrosis factor (TNF) blocker or an interleukin-17 ( ...

  8. Clinical Trials - Division of Infectious Diseases

    However, many CD and UC patients still ultimately require surgery despite the use of these medications. Side effects of the anti-TNF agents include increased ...

  9. Head-to-head comparison between vedolizumab and adalimumab for treatment of moderately to severely active ulcerative colitis - Mayo Clinic

    The Food and Drug Administration approved the use of anti-tumor necrosis factor and anti-integrin agents for the treatment of ulcerative colitis in 2005 ...

  10. Adalimumab-Aacf (Subcutaneous Route) Proper Use - Mayo Clinic

    This medicine comes with a Medication Guide and patient instructions. Read and follow these instructions carefully. Ask your doctor if you have any questions.